

# Lisa A Carey

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8324475/publications.pdf>

Version: 2024-02-01

251  
papers

31,076  
citations

6606

79  
h-index

4770

169  
g-index

258  
all docs

258  
docs citations

258  
times ranked

30287  
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimal Endocrine Therapy in Premenopausal Women: A Pragmatic Approach to Unanswered Questions. <i>JCO Oncology Practice</i> , 2022, 18, 211-216.	1.4	10
2	The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1258-1267.	3.2	31
3	CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1323-1334.	0.8	62
4	Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer. , 2022, 10, e003427.		11
5	Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	4
6	Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response. <i>NAR Cancer</i> , 2022, 4, .	1.6	10
7	Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancerâ€”phase 3 ASCENT study subanalysis. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	25
8	Prognostic and predictive implications of the intrinsic subtypes and gene expression signatures in early-stage HER2+ breast cancer: A pooled analysis of CALGB 40601, NeoALTTO, and NSABP B-41 trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 509-509.	0.8	4
9	A single-arm feasibility trial of memantine to prevent chemotherapy-related cognitive decline in patients with early breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 12109-12109.	0.8	0
10	Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptorâ€”Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3618-3629.	3.2	12
11	Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa072.	1.4	14
12	Patientâ€”reported symptom severity, interference with daily activities, and adverse events in older and younger women receiving chemotherapy for early breast cancer. <i>Cancer</i> , 2021, 127, 957-967.	2.0	7
13	Obesity, comorbidities, and treatment selection in Black and White women with early breast cancer. <i>Cancer</i> , 2021, 127, 922-930.	2.0	23
14	The Global Landscape of Treatment Standards for Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1143-1155.	3.0	13
15	Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptorâ€”Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Antiâ€”HER2-Based Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 3116-3125.	3.2	9
16	Benchmarks for Academic Oncology Faculty. <i>JCO Oncology Practice</i> , 2021, 17, e440-e444.	1.4	1
17	Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 1529-1541.	13.9	601
18	Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). <i>Annals of Surgical Oncology</i> , 2021, 28, 5960-5971.	0.7	22

#	ARTICLE	IF	CITATIONS
19	Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance). <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab025.	1.4	8
20	ASO Visual Abstract: Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). <i>Annals of Surgical Oncology</i> , 2021, 28, 436-437.	0.7	0
21	Finding the positive in triple-negative breast cancer. <i>Nature Cancer</i> , 2021, 2, 476-478.	5.7	3
22	Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2021, 39, 1485-1505.	0.8	395
23	FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036. <i>Npj Breast Cancer</i> , 2021, 7, 51.	2.3	11
24	RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4883-4897.	3.2	11
25	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptorâ€“Negative: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 3938-3958.	0.8	40
26	Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy. <i>EBioMedicine</i> , 2021, 69, 103451.	2.7	7
27	Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2247-2256.	0.8	22
28	Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13â€“864 women in seven randomised trials. <i>Lancet Oncology</i> , The, 2021, 22, 1139-1150.	5.1	147
29	A plain language summary of the ASCENTâ€“study: Sacituzumab Govitecan for metastatic triple-negative breast cancer. <i>Future Oncology</i> , 2021, 17, 3911-3924.	1.1	9
30	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. <i>Annals of Oncology</i> , 2021, 32, 1216-1235.	0.6	354
31	Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1+ tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. <i>Future Oncology</i> , 2021, 17, 4665-4676.	1.1	8
32	Race and smoking status associated with paclitaxel drug response in patient-derived lymphoblastoid cell lines. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 48-52.	0.7	0
33	A chemotherapy privileging process for advanced practice providers at an academic medical center. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 116-123.	0.5	2
34	Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classifications. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 185-195.	1.1	11
35	Weight trajectories in women receiving systemic adjuvant therapy for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 709-720.	1.1	20
36	Borderline Estrogen Receptorâ€“Positive Breast Cancers in Black and White Women. <i>Journal of the National Cancer Institute</i> , 2020, 112, 728-736.	3.0	19

#	ARTICLE	IF	CITATIONS
37	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 597-609.	13.9	789
38	Effects of Breast Cancer Adjuvant Chemotherapy Regimens on Expression of the Aging Biomarker, <i>p16INK4a</i> . <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa082.	1.4	15
39	Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 4184-4193.	0.8	74
40	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. <i>Lancet Oncology</i> , The, 2020, 21, 1455-1464.	5.1	52
41	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. <i>Journal of Clinical Oncology</i> , 2020, 38, 4274-4282.	0.8	276
42	Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2610-2619.	0.8	331
43	Integrating Biology and Access to Care in Addressing Breast Cancer Disparities: 25 Years' Research Experience in the Carolina Breast Cancer Study. <i>Current Breast Cancer Reports</i> , 2020, 12, 149-160.	0.5	4
44	Clinical Significance of Circulating Tumor Cells in Hormone Receptor-positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab. <i>Clinical Cancer Research</i> , 2020, 26, 4911-4920.	3.2	14
45	What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer?. <i>Clinical Cancer Research</i> , 2020, 26, 2783-2788.	3.2	27
46	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2020, 84, 101965.	3.4	92
47	Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 1346-1366.	0.8	673
48	Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 545-563.	1.2	205
49	Congruence of patient- and clinician-reported toxicity in women receiving chemotherapy for early breast cancer. <i>Cancer</i> , 2020, 126, 3084-3093.	2.0	25
50	FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. <i>Journal of Clinical Investigation</i> , 2020, 130, 4871-4887.	3.9	49
51	Race and delays in breast cancer treatment across the care continuum in the Carolina Breast Cancer Study. <i>Cancer</i> , 2019, 125, 3985-3992.	2.0	35
52	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, <i>Research Directions</i> . <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz049.	1.4	11
53	Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 2338-2348.	0.8	56
54	Toronto Workshop on Late Recurrence in Estrogen Receptor-positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, <i>Clinical Considerations</i> . <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz050.	1.4	15

#	ARTICLE	IF	CITATIONS
55	Risk factors for Luminal A ductal carcinoma in situ (DCIS) and invasive breast cancer in the Carolina Breast Cancer Study. <i>PLoS ONE</i> , 2019, 14, e0211488.	1.1	10
56	Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2189-2192.	0.8	12
57	Patientâ€“reported and clinicianâ€“reported chemotherapyâ€“induced peripheral neuropathy in patients with early breast cancer: Current clinical practice. <i>Cancer</i> , 2019, 125, 2945-2954.	2.0	60
58	Localâ€“regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). <i>Breast Cancer Research and Treatment</i> , 2019, 176, 303-310.	1.1	30
59	Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 321-328.	1.1	17
60	Older-Patient-Specific Cancer Trials: A Pooled Analysis of 2,277 Patients (A151715). <i>Oncologist</i> , 2019, 24, e284-e291.	1.9	4
61	TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 714-722.	0.8	36
62	Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer. <i>Oncologist</i> , 2019, 24, 762-771.	1.9	56
63	Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 1868-1875.	0.8	229
64	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37â€“298 women with early breast cancer in 26 randomised trials. <i>Lancet, The</i> , 2019, 393, 1440-1452.	6.3	260
65	Research priorities in prediction of response in early breast cancer. <i>Breast</i> , 2019, 48, S31-S33.	0.9	1
66	HITTING A MOVING TARGET: 2019 STANDARDS OF CARE AND TREATMENT OPTIMIZATION FOR HER2+ ABC. <i>Breast</i> , 2019, 48, S29-S30.	0.9	0
67	Endocrine Therapy Nonadherence and Discontinuation in Black and White Women. <i>Journal of the National Cancer Institute</i> , 2019, 111, 498-508.	3.0	65
68	Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials.. <i>Journal of Clinical Oncology</i> , 2019, 37, 571-571.	0.8	6
69	PAM50 and Risk of Recurrence Scores for Interval Breast Cancers. <i>Cancer Prevention Research</i> , 2018, 11, 327-336.	0.7	7
70	Influence of provider factors and race on uptake of breast cancer gene expression profiling. <i>Cancer</i> , 2018, 124, 1743-1751.	2.0	8
71	Asparagine bioavailability governs metastasis in a model of breast cancer. <i>Nature</i> , 2018, 554, 378-381.	13.7	362
72	A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, 289-297.	1.1	21

#	ARTICLE	IF	CITATIONS
73	Weight gain in hormone receptor-positive (HR+) early-stage breast cancer: is it menopausal status or something else?. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 235-248.	1.1	8
74	Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. <i>Journal of the National Cancer Institute</i> , 2018, 110, 176-182.	3.0	104
75	Changing Natural History of HER2-Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies. <i>Clinical Breast Cancer</i> , 2018, 18, 29-37.	1.1	35
76	Financial Impact of Breast Cancer in Black Versus White Women. <i>Journal of Clinical Oncology</i> , 2018, 36, 1695-1701.	0.8	85
77	Evolution of Targeted Therapy in Breast Cancer: Where Precision Medicine Began. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 78-86.	1.8	36
78	A prognostic model integrating clinical data and gene signatures in phase III neoadjuvant trial CALGB 40601 (Alliance). <i>Annals of Oncology</i> , 2018, 29, vii50.	0.6	0
79	LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 637-648.	1.1	40
80	Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5292-5304.	3.2	73
81	Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 111-120.	1.1	38
82	Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 1371-1383.	3.9	126
83	Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative). <i>Journal of the American College of Surgeons</i> , 2017, 224, 688-694.	0.2	8
84	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex. <i>Cancer Discovery</i> , 2017, 7, 302-321.	7.7	128
85	Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). <i>Journal of Clinical Oncology</i> , 2017, 35, 1061-1069.	0.8	254
86	Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. <i>JAMA Oncology</i> , 2017, 3, 1043.	3.4	98
87	Weight changes in postmenopausal breast cancer survivors over 2 years of endocrine therapy: a retrospective chart review. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 375-388.	1.1	16
88	Unmet Needs in Clinical Research in Breast Cancer: Where Do We Need to Go?. <i>Clinical Cancer Research</i> , 2017, 23, 2611-2616.	3.2	18
89	Evaluating the Effectiveness of Neoadjuvant Chemotherapy in Reducing Mastectomy for Women With Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2017, 1, pkx004.	1.4	3
90	Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302). <i>Breast Cancer Research and Treatment</i> , 2017, 166, 793-808.	1.1	11

#	ARTICLE	IF	CITATIONS
91	De-escalating and escalating systemic therapy in triple negative breast cancer. <i>Breast</i> , 2017, 34, S112-S115.	0.9	12
92	Treating Triple Negative ABC. <i>Breast</i> , 2017, 36, S30-S31.	0.9	0
93	Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). <i>Breast Cancer Research and Treatment</i> , 2017, 165, 181-191.	1.1	54
94	Comparative Toxicity and Effectiveness of Trastuzumab-Based Chemotherapy Regimens in Older Women With Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3298-3305.	0.8	47
95	Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer. <i>Journal of Clinical Investigation</i> , 2017, 127, 3472-3483.	3.9	130
96	Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases. <i>PLoS Medicine</i> , 2016, 13, e1002174.	3.9	86
97	I-SPY 2 â€” Toward More Rapid Progress in Breast Cancer Treatment. <i>New England Journal of Medicine</i> , 2016, 375, 83-84.	13.9	47
98	PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). <i>Npj Breast Cancer</i> , 2016, 2, .	2.3	80
99	Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity. <i>Oncologist</i> , 2016, 21, 795-803.	1.9	42
100	Another Breast Cancer Entity Confirmed: Genomics of Invasive Lobular Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1838-1839.	0.8	5
101	Disparities in Use of Human Epidermal Growth Hormone Receptor 2â€™ Targeted Therapy for Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2003-2009.	0.8	64
102	Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 1557.	3.4	242
103	Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptorâ€™ Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). <i>Journal of Clinical Oncology</i> , 2016, 34, 2602-2609.	0.8	101
104	Breast cancer biologic and etiologic heterogeneity by young age and menopausal status in the Carolina Breast Cancer Study: a case-control study. <i>Breast Cancer Research</i> , 2016, 18, 79.	2.2	88
105	Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426). <i>Breast Cancer Research and Treatment</i> , 2016, 159, 109-118.	1.1	47
106	Neoadjuvant Systemic Therapy Use for Younger Patients with Breast Cancer Treated in Different Types of Cancer Centers Across the United States. <i>Journal of the American College of Surgeons</i> , 2016, 223, 717-728e4.	0.2	19
107	Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage IIâ€™III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). <i>Breast Cancer Research and Treatment</i> , 2016, 160, 297-304.	1.1	63
108	Breast Cancer Screening in Low- and Middle-Income Countries: A Perspective From Malawi. <i>Journal of Global Oncology</i> , 2016, 2, 4-8.	0.5	34



#	ARTICLE	IF	CITATIONS
109	Racial Variation in the Uptake of OncoDX Testing for Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 130-138.	0.8	46
110	A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience. <i>Oncologist</i> , 2016, 21, 16-20.	1.9	33
111	Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 29.	3.4	68
112	Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. <i>Journal of Clinical Oncology</i> , 2016, 34, 542-549.	0.8	336
113	In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1122-1130.	1.1	40
114	CCR 20th Anniversary Commentary: Simpson's Paradox and Neoadjuvant Trials. <i>Clinical Cancer Research</i> , 2015, 21, 4027-4029.	3.2	4
115	Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 134-141.	13.9	598
116	The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: Triple-Negative Breast Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 874-882.	0.7	91
117	The Use of Bayesian Hierarchical Models for Adaptive Randomization in Biomarker-Driven Phase II Studies. <i>Journal of Biopharmaceutical Statistics</i> , 2015, 25, 66-88.	0.4	9
118	Palbociclib Taking Breast-Cancer Cells Out of Gear. <i>New England Journal of Medicine</i> , 2015, 373, 273-274.	13.9	13
119	Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). <i>Journal of Clinical Oncology</i> , 2015, 33, 2361-2369.	0.8	197
120	Old drugs, new tricks for triple-negative breast cancer. <i>Lancet Oncology</i> , The, 2015, 16, 357-359.	5.1	7
121	Race, response to chemotherapy, and outcome within clinical breast cancer subtypes. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 667-674.	1.1	41
122	Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression. <i>Oncologist</i> , 2015, 20, 474-482.	1.9	145
123	Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). <i>Breast Cancer Research and Treatment</i> , 2015, 151, 589-596.	1.1	65
124	TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1902-1909.	0.8	351
125	Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains. <i>Cell Reports</i> , 2015, 11, 390-404.	2.9	254
126	Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 347-356.	1.1	38



#	ARTICLE	IF	CITATIONS
127	Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 191-200.	1.1	15
128	Neoadjuvant clinical trial designs: Challenges of the genomic era. <i>Breast</i> , 2015, 24, S88-S90.	0.9	3
129	Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers. <i>Clinical Cancer Research</i> , 2015, 21, 1098-1105.	3.2	35
130	TBCRC 008: Early Change in $^{18}\text{F}$ -FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2 $^{\text{--}}$ Negative Primary Operable Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 31-37.	2.8	61
131	Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). <i>Journal of Clinical Oncology</i> , 2015, 33, 13-21.	0.8	782
132	A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 99-106.	1.1	16
133	Making Sense of Dual HER2-Targeting in Early Breast Cancer?. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju259-dju259.	3.0	1
134	Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer. <i>Science Signaling</i> , 2014, 7, ra29.	1.6	123
135	Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	178
136	Effect of Cytotoxic Chemotherapy on Markers of Molecular Age in Patients With Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju057.	3.0	218
137	How Low Should We Go? The Search for Balance in Management of Small Human Epidermal Growth Factor Receptor 2 $^{\text{--}}$ Positive Breast Cancers. <i>Journal of Clinical Oncology</i> , 2014, 32, 2122-2124.	0.8	8
138	Age-Specific Changes in Intrinsic Breast Cancer Subtypes: A Focus on Older Women. <i>Oncologist</i> , 2014, 19, 1076-1083.	1.9	122
139	Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 3818-3829.	3.2	230
140	Defining success in neoadjuvant breast cancer trials. <i>Lancet, The</i> , 2014, 384, 115-116.	6.3	20
141	Novel Methylated Biomarkers and a Robust Assay to Detect Circulating Tumor DNA in Metastatic Breast Cancer. <i>Cancer Research</i> , 2014, 74, 2160-2170.	0.4	149
142	$\beta$ -Crystallin: A Novel Regulator of Breast Cancer Metastasis to the Brain. <i>Clinical Cancer Research</i> , 2014, 20, 56-67.	3.2	87
143	Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2 $^{\text{--}}$ Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 3307-3329.	0.8	210
144	TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 557-566.	1.1	59

#	ARTICLE	IF	CITATIONS
145	Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 245-254.	1.1	41
146	Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa).. <i>Journal of Clinical Oncology</i> , 2014, 32, 506-506.	0.8	13
147	Understanding how breast cancer patients use risk information from genomic tests. <i>Journal of Behavioral Medicine</i> , 2013, 36, 567-573.	1.1	13
148	The Management of Early-Stage and Metastatic Triple-Negative Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 737-749.	0.9	80
149	Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 5505-5512.	3.2	592
150	Dysregulation of the epigenome in triple-negative breast cancers: Basal-like and claudin-low breast cancers express aberrant DNA hypermethylation. <i>Experimental and Molecular Pathology</i> , 2013, 95, 276-287.	0.9	59
151	Emerging therapies for triple-negative breast cancer. <i>Breast Cancer Management</i> , 2013, 2, 47-55.	0.2	1
152	Disparities in Breast Cancer Treatment and Outcomes: Biological, Social, and Health System Determinants and Opportunities for Research. <i>Oncologist</i> , 2013, 18, 986-993.	1.9	197
153	Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer. <i>Oncologist</i> , 2013, 18, 123-133.	1.9	454
154	Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer. <i>PLoS ONE</i> , 2013, 8, e61359.	1.1	77
155	Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 500-500.	0.8	57
156	Engaging in Health Behaviors to Lower Risk for Breast Cancer Recurrence. <i>PLoS ONE</i> , 2013, 8, e53607.	1.1	32
157	ACR Appropriateness Criteria® Local-regional Recurrence (LR) and Salvage Surgery. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 178-182.	0.6	12
158	Neoadjuvant Trials of Human Epidermal Growth Factor Receptor 2 Targeting: How Many Drugs Do We Need?. <i>Journal of Clinical Oncology</i> , 2012, 30, 1909-1911.	0.8	4
159	Phase I Study and Biomarker Analysis of Lapatinib and Concurrent Radiation for Locally Advanced Breast Cancer. <i>Oncologist</i> , 2012, 17, 1496-1503.	1.9	13
160	TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 2615-2623.	0.8	413
161	Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 35-43.	1.1	88
162	Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL® CALGB 150007/150012, ACRIN 6657. <i>Journal of Clinical Oncology</i> , 2012, 30, 3242-3249.	0.8	379

#	ARTICLE	IF	CITATIONS
163	HER2 is a good addiction. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 196-197.	12.5	16
164	Defining the expressed breast cancer kinome. <i>Cell Research</i> , 2012, 22, 620-623.	5.7	23
165	CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 401-410.	1.1	81
166	The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1189-1196.	1.1	16
167	Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 523-535.	1.1	189
168	Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial). <i>Breast Cancer Research and Treatment</i> , 2012, 132, 871-879.	1.1	26
169	Improving communication of breast cancer recurrence risk. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 553-561.	1.1	64
170	Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). <i>Breast Cancer Research and Treatment</i> , 2012, 132, 1049-1062.	1.1	286
171	A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 1057-1065.	1.1	183
172	ACR Appropriateness Criteria® Ductal Carcinoma in Situ. <i>Breast Journal</i> , 2012, 18, 8-15.	0.4	19
173	Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer. <i>Annals of Surgical Oncology</i> , 2012, 19, 1508-1516.	0.7	401
174	Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 3232-3239.	0.8	173
175	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. <i>Nature Genetics</i> , 2011, 43, 1210-1214.	9.4	279
176	PARP and Cancer - If It's Broke, Don't Fix It. <i>New England Journal of Medicine</i> , 2011, 364, 277-279.	13.9	52
177	Clinical trials in triple negative breast cancer. <i>Breast Disease</i> , 2011, 32, 123-136.	0.4	28
178	ACR Appropriateness Criteria® Conservative surgery and Radiation - Stage I and II Breast Carcinoma. <i>Breast Journal</i> , 2011, 17, 448-455.	0.4	26
179	ACR Appropriateness Criteria® Locally Advanced Breast Cancer. <i>Breast Journal</i> , 2011, 17, 579-585.	0.4	16
180	Impact of Breast Cancer Molecular Subtypes on Locoregional Recurrence in Patients Treated with Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer. <i>Annals of Surgical Oncology</i> , 2011, 18, 2851-2857.	0.7	84

#	ARTICLE	IF	CITATIONS
181	Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. <i>BMC Medical Genomics</i> , 2011, 4, 3.	0.7	142
182	The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. <i>Cancer</i> , 2011, 117, 1602-1611.	2.0	125
183	Directed Therapy of Subtypes of Triple-Negative Breast Cancer. <i>Oncologist</i> , 2011, 16, 71-78.	1.9	148
184	Breast Carcinomas Arising at a Young Age: Unique Biology or a Surrogate for Aggressive Intrinsic Subtypes?. <i>Journal of Clinical Oncology</i> , 2011, 29, e18-e20.	0.8	200
185	Young women with locally advanced breast cancer who achieve breast conservation after neoadjuvant chemotherapy have a low local recurrence rate. <i>American Surgeon</i> , 2011, 77, 850-5.	0.4	12
186	Novel targets for triple-negative breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2011, 9, 678-80.	0.3	3
187	Phase II Study of Bortezomib and Pegylated Liposomal Doxorubicin in the Treatment of Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2010, 10, 465-470.	1.1	30
188	Women's experiences with genomic testing for breast cancer recurrence risk. <i>Cancer</i> , 2010, 116, 1992-2000.	2.0	48
189	Altered-Function p53 Missense Mutations Identified in Breast Cancers Can Have Subtle Effects on Transactivation. <i>Molecular Cancer Research</i> , 2010, 8, 701-716.	1.5	57
190	Poly(ADP-Ribose) Polymerase Inhibition: "Targeted" Therapy for Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 4702-4710.	3.2	149
191	Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study. <i>Clinical Cancer Research</i> , 2010, 16, 6100-6110.	3.2	351
192	Targeted Chemotherapy? Platinum in BRCA1-Dysfunctional Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 361-363.	0.8	34
193	Directed Therapy of Subtypes of Triple-Negative Breast Cancer. <i>Oncologist</i> , 2010, 15, 49-56.	1.9	44
194	Through a Glass Darkly: Advances in Understanding Breast Cancer Biology, 2000-2010. <i>Clinical Breast Cancer</i> , 2010, 10, 188-195.	1.1	39
195	Triple-negative breast cancer: disease entity or title of convenience?. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 683-692.	12.5	708
196	Lower-Dose vs High-Dose Oral Estradiol Therapy of Hormone Receptor-Positive, Aromatase Inhibitor-Resistant Advanced Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 774.	3.8	252
197	Breast Cancer Molecular Subtypes in Patients With Locally Advanced Disease: Impact on Prognosis, Patterns of Recurrence, and Response to Therapy. <i>Seminars in Radiation Oncology</i> , 2009, 19, 204-210.	1.0	103
198	A compact VEGF signature associated with distant metastases and poor outcomes. <i>BMC Medicine</i> , 2009, 7, 9.	2.3	162

#	ARTICLE	IF	CITATIONS
199	Improved Surgical Outcomes for Breast Cancer Patients Receiving Neoadjuvant Aromatase Inhibitor Therapy: Results from a Multicenter Phase II Trial. <i>Journal of the American College of Surgeons</i> , 2009, 208, 906-914.	0.2	74
200	When genomic and standard test results diverge: implications for breast cancer patients' preference for chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 25-29.	1.1	20
201	Reporting of race and ethnicity in breast cancer research: room for improvement. <i>Breast Cancer Research and Treatment</i> , 2009, 118, 511-517.	1.1	17
202	CYP2D6 and tamoxifen: DNA matters in breast cancer. <i>Nature Reviews Cancer</i> , 2009, 9, 576-586.	12.8	287
203	A desensitization protocol for the mAb cetuximab. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 123, 260-262.	1.5	38
204	Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2009, 9, S73-S81.	1.1	546
205	Epidemiology of basal-like breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 109, 123-139.	1.1	747
206	A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 63, 99-107.	1.1	22
207	Polymorphisms in drug metabolism genes, smoking, and p53 mutations in breast cancer. <i>Molecular Carcinogenesis</i> , 2008, 47, 88-99.	1.3	23
208	Molecular Subtypes in Breast Cancer Evaluation and Management: Divide and Conquer. <i>Cancer Investigation</i> , 2008, 26, 1-10.	0.6	170
209	What is triple-negative breast cancer?. <i>European Journal of Cancer</i> , 2008, 44, 2799-2805.	1.3	270
210	Triple-Negative Breast Cancer: Risk Factors to Potential Targets. <i>Clinical Cancer Research</i> , 2008, 14, 8010-8018.	3.2	380
211	Genotype-guided adjuvant endocrine therapy: new tricks from an old drug?. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 191-194.	1.1	1
212	Research Issues Affecting Preoperative Systemic Therapy for Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 806-813.	0.8	68
213	Guidelines for the Initial Management of Metastatic Brain Tumors: Role of Surgery, Radiosurgery, and Radiation Therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008, 6, 505-514.	2.3	58
214	Basal-like breast cancers express a hypermethylation defect. <i>FASEB Journal</i> , 2008, 22, 898.23.	0.2	0
215	Understanding and treating triple-negative breast cancer. <i>Oncology</i> , 2008, 22, 1233-9; discussion 1239-40, 1243.	0.4	179
216	Polymorphisms in CYP1B1, GSTM1, GSTT1 and GSTP1, and susceptibility to breast cancer. <i>Oncology Reports</i> , 2008, 19, 1311-21.	1.2	33

#	ARTICLE	IF	CITATIONS
217	Molecular Subtypes in Breast Cancer Evaluation and Management: Divide and Conquer. Translational Medicine Series, 2007, , 103-120.	0.0	0
218	Blood Vessel Morphologic Changes Depicted with MR Angiography during Treatment of Brain Metastases: A Feasibility Study. Radiology, 2007, 245, 824-830.	3.6	37
219	Gene-expression analysis and the basal-like breast cancer subtype. Future Oncology, 2007, 3, 55-63.	1.1	32
220	Women's Interest in Gene Expression Analysis for Breast Cancer Recurrence Risk. Journal of Clinical Oncology, 2007, 25, 4628-4634.	0.8	42
221	Retention and Use of Breast Cancer Recurrence Risk Information from Genomic Tests: The Role of Health Literacy. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 249-255.	1.1	77
222	Treatment of Single Brain Metastasis with Resection, Intracavity Carmustine Polymer Wafers, and Radiation Therapy Is Safe and Provides Excellent Local Control. Clinical Cancer Research, 2007, 13, 3637-3641.	3.2	83
223	Gene expression profiling in breast cancer. Current Opinion in Oncology, 2007, 19, 547-551.	1.1	46
224	The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes. Clinical Cancer Research, 2007, 13, 2329-2334.	3.2	1,786
225	Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer. Breast Cancer Research, 2007, 9, 110.	2.2	18
226	EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics, 2007, 8, 258.	1.2	234
227	Molecular profiling in breast cancer. Reviews in Endocrine and Metabolic Disorders, 2007, 8, 185-198.	2.6	35
228	Response and Cardiac Toxicity of Trastuzumab Given in Conjunction with Weekly Paclitaxel After Doxorubicin/Cyclophosphamide. Clinical Breast Cancer, 2006, 7, 237-243.	1.1	38
229	Axillary lymph node count is lower after neoadjuvant chemotherapy. American Journal of Surgery, 2006, 191, 827-829.	0.9	66
230	Clonal evolution of lymphoblastoid cell lines. Laboratory Investigation, 2006, 86, 1193-1200.	1.7	31
231	Size of Residual Lymph Node Metastasis After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients Is Prognostic. Annals of Surgical Oncology, 2006, 13, 685-691.	0.7	67
232	The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics, 2006, 7, 96.	1.2	1,169
233	Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study. JAMA - Journal of the American Medical Association, 2006, 295, 2492.	3.8	3,135
234	Radiation clastogenesis and cell cycle checkpoint function as functional markers of breast cancer risk. Carcinogenesis, 2006, 27, 2519-2527.	1.3	14

#	ARTICLE	IF	CITATIONS
235	Estrogen-Regulated Genes Predict Survival in Hormone Receptor-Positive Breast Cancers. <i>Journal of Clinical Oncology</i> , 2006, 24, 1656-1664.	0.8	300
236	Current Treatment Paradigms for the Management of Patients with Brain Metastases. <i>Neurosurgery</i> , 2005, 57, S4-66-S4-77.	0.6	76
237	American Joint Committee on Cancer Tumor-Node-Metastasis Stage After Neoadjuvant Chemotherapy and Breast Cancer Outcome. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1137-1142.	3.0	185
238	Molecular Portraits and 70-Gene Prognosis Signature Are Preserved throughout the Metastatic Process of Breast Cancer. <i>Cancer Research</i> , 2005, 65, 9155-9158.	0.4	302
239	Lymphatic mapping and sentinel lymphadenectomy prior to neoadjuvant chemotherapy in patients with large breast cancers. <i>American Journal of Surgery</i> , 2005, 190, 371-375.	0.9	35
240	Central nervous system metastases in women after multimodality therapy for high risk breast cancer. <i>Breast Cancer Research and Treatment</i> , 2004, 88, 273-280.	1.1	50
241	Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 777-785.	2.0	31
242	High-resolution axillary ultrasound is a poor prognostic test for determining pathologic lymph node status in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer. <i>American Journal of Surgery</i> , 2004, 188, 386-389.	0.9	21
243	Long-Term Outcome of Neoadjuvant Therapy for Locally Advanced Breast Carcinoma. <i>Annals of Surgery</i> , 2002, 236, 295-303.	2.1	119
244	Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. <i>Annals of Surgery</i> , 2002, 236, 295-302; discussion 302-3.	2.1	65
245	Clinical Significance of Micrometastatic Disease in the Era of Sentinel Node. <i>Breast Disease</i> , 2001, 12, 57-67.	0.4	1
246	Brain metastases. <i>Current Treatment Options in Oncology</i> , 2001, 2, 537-547.	1.3	28
247	Telomerase Activity and Prognosis in Primary Breast Cancers. <i>Journal of Clinical Oncology</i> , 1999, 17, 3075-3081.	0.8	52
248	Tuberculin skin test reactivity, anergy, and HIV infection in hospitalized patients. <i>American Journal of Medicine</i> , 1996, 100, 186-192.	0.6	28
249	Treatment of melanoma metastases in the brain. , 1996, 12, 429-435.		37
250	Quantifying the effect of ischemia on epiphyseal growth in an extremity replant model. <i>Journal of Hand Surgery</i> , 1990, 15, 625-630.	0.7	18
251	Oxygen Radical Scavengers Improve Vascular Patency and Bone-Muscle Cell Survival in an Ischemic Extremity Replant Model. <i>Plastic and Reconstructive Surgery</i> , 1989, 84, 117-123.	0.7	24